OA
ROIV icon

Oracle Alpha’s Roivant Sciences ROIV Stock Holding History

Oracle Alpha’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$390K Buy
37,039
+20,438
+123% +$220K 0.7% 37
2023
Q4 		$186K Buy
+16,601
New +$162K 0.24% 198

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Oracle Alpha's ROIV Position: Q1 2024 in Review

Oracle Alpha increased its Roivant Sciences (ROIV) stake by 123% in Q1 2024, buying an estimated $220K and bringing the position to 37,039 shares worth $390K. The position accounts for 0.7% of the portfolio, ranked #37.

Oracle Alpha first reported a position in ROIV in Q4 2023 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold ROIV as of Q1 2024.

  • Oracle Alpha held 37,039 shares of Roivant Sciences worth $390K as of Q1 2024.
  • Oracle Alpha bought 20,438 Roivant Sciences shares in Q1 2024, an estimated $220K.
  • Roivant Sciences made up 0.7% of Oracle Alpha's portfolio in Q1 2024, its #37 holding.
  • Oracle Alpha first reported a position in Roivant Sciences in Q4 2023 and has held it in 2 quarters since.
  • 260 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.